medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2000, Number 4

<< Back Next >>

Rev Biomed 2000; 11 (4)

The Amikacin on premature newborn: schema of treatment defined by gestational and postnatal age

Cervantes-Munguía R, Trujillo-López JJ, Vásquez-Garibay E, Rivera-Madrigal MJ, Hernández-Flores G, Orbach-Arbouys S, Bravo-Cuellar A

Language: English
References: 17
Page: 251-256
PDF size: 29.37 Kb.


ABSTRACT

Introduction. Amikacin (AMK) is an antibiotic of the aminiglycosides family frequently used against infections caused by gram negative bacteria in the newborn. It is necessary to get defined serum concentrations to obtain the highest efficiency and the lowest toxicity. The classic protocols generally drive to higher plasmatic concentrations than those recommended. That is why, on premature newborn, we used a protocol taking into account weight gestational and the postnatal age, all at the same time, since the physiological constants of the newborn evolve change quickly.
Material and methods. This protocol has been compared to the protocol usually used in our Hospital, that doesn't take those features of the postnatal age into account. The study was carried out on 112 prematures forming four groups, distributed according to their gestational and postnatal age. All received AMK at the dose of 7,5 mg/kg of weight, only the administration rhythms differed. Our schema proposed of AMK administration: every 24 hours to the premature of less than 33 weeks of gestational age an less or more than 7 days of life, every 18 hours to prematures from 33 to 36 weeks with a postnatal age of 6 days or less and every 12 hours to those aged 7 to 21 days.
Results. AMK serum peak and trough concentrations were maintained within recommended limits and the posology did not have to be adjusted more than a few times.
Discussion. These results permit us to recommend this schema in special on those hospitals which don't have the technological support for the serum determination of AMK.


REFERENCES

  1. Sande M, Mandell G. Antimicrobial agents.The aminiglycosides. In :Goodman A, Rall T Nies A , Taylor P, Eds. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1991. p. 1098-107.

  2. Fanos V, Mussap M, Verlato G, Pleban M, Padovani EM. Evaluation of antibiotic-induced nephrotoxicity in preterm neonates in determing urinary alpha 1 microglobulin. Pediatr Nephrol 1996; 10: 645-7.

  3. Rose E. Pharmacodynamics: Mechanisms of drug action and the relationship between drug concentration and effect. In: Goodman A,Rall T, Nies A, Taylor P, Eds. The pharmacological basis of therapeutics. 8th ed. New York. Pergamon Press; 1991. p. 33-48.

  4. McCracken G, Nelson J. Pharmacologic concepts in the newborn. In: McCracken G. Jr, Nelson J. ed. Antimicrobial therapy for newborns. 2nd ed. New York: Grune & Stratton; 1983. p. 3-7.

  5. Andronikou S, Giapros VI, Cholevas VI, Papadopoulou ZL. Effect of aminoglycosides therapy on renal function in full-term infants. Pediatr Nephrol 1996; 10: 766-8.

  6. Nanri S, Sunakawa N, Yanashita NA. A pharmacokinetic study in mature and premature neonates treated with amikacin through intravenous drop infusion. Jpn J Antibiot 1987; 40: 1135-45.

  7. Phillips JB, Satterwithe C, Dworsky ME, Cassady G. Recommended amikacin doses in newborns often produce excessive serum levels. Pediatr Pharm 1987; 121-125.

  8. Kenyon CF, Knoppert DC, Lee SK, Vandenberghe HM, Chance GW. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 1990; 34: 265-8.

  9. Marx C, Cronion J. Medications used in the newborm. In: Cloherty J, Stark AR, Eds. Manual of Neonatal Care. 3rd ed. Boston: Brown & Co; 1991. p. 619.

  10. 10.Gomella TL, Cunninham MD. Commonly used antibiotics. In: Gomella TL, Cunninham MD. Eds. Neonatalogy, basic management, on-call problems, disease, drugs. Norwalk: Appleton and Lange; 1988. p. 384-96.

  11. Guinar J. Renal function in the newborn infant. Pediat Clin North Am 1982; 77: 90-4.

  12. Ballard JL, Khoury JL, Weding K, Wang L, Ellers-Walsman BL, Lipp R. New Ballard score, expanded to include extremely premature infants. J Pediatr 1991; 119: 417-23.

  13. Yow MD. On overview of pediatric experience with Amikacin. Am J Med 1977; 62: 954-68.

  14. Trujillo H, Manotas R, Londome R, et al. Clinical and laboratory studies with amikacin in newborns, infants and children. J Inf Dis 1976; 134: 406-11.

  15. Freeman CD, Nicoleau DP, Belliveau PP, Nightingale CH. Once daily dosing aminiglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-86.

  16. Forsyth NB, Botha JH, Hadley GP. A comparison of two amikacin dosing regimens in pediatric surgical patients. Ann Trop Pediatr 1997; 17: 253-61.

  17. Langhendries JP, Darimont J, Wallemacq P, Scalais E. Amikacine en dose unitaire en néonatalogie: rythme optimal d’administration en fonction de l’âge gestationnel et de la pathologie. La Lettre de l’ Infectiologue 1995; Hors série, juin,: 34-38.




2020     |     www.medigraphic.com